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Objectives. To estimate the health effects of
postmenopausal hormone therapy used for 10 or
20 years in a population of intermediate cardiovas-
cular risk.
Design. Using existing estimates of the effect of
hormone therapy on rates of myocardial infarction,
hip fracture and breast cancer, a proportional
multistage life table was generated to calculate the
effects of use for 10 and 20 years in a synthetic cohort
of Dutch women aged 55 with an average and a high-
risk profile for cardiovascular disease.
Results. A woman of the general population who
starts hormone therapy at age 55 for 10 years can
prolong her life by 1 month and may postpone the
occurrence of first incidence of one of the diseases
under consideration by 2.4 months. One excess
breast cancer case is likely to occur per 5±6 averted
cases of first myocardial infarction or hip fracture. If
she prolongs her use to 20 years, the gain of life
expectancy and disease-free life expectancy is
doubled. The risk±benefit ratio worsens to one extra
breast cancer per 3±4 averted cases of the preventable
diseases. For a woman with a high-risk profile, the
gains in health are about twice as high as for her
counterpart in the general population, and her risk±
benefit ratio is also more favourable. Yet, the risk±
benefit ratio still worsens for 20 as compared with
10 years of use.
Conclusions. Women from the general population in
the Netherlands and similar populations can achieve
only a modest gain in life expectancy by using
hormones during 10 or 20 years following meno-
pause. This is a consequence of the low incidence of
myocardial infarction and hip fracture and the
relatively high incidence of breast cancer before
the age of 75. Women at increased cardiovascular risk
can benefit more from hormone therapy. But even
amongst these women, the risk of breast cancer
incurred with long-term use offsets much of the
benefit that could accrue from changing the risk of
heart disease and hip fracture.
Keywords: breast neoplasms, coronary heart dis-
ease, hip fractures, hormone replacement therapy,
middle age, models: theoretical.
Introduction
Long-term use of postmenopausal hormone therapy
is advocated as a preventive measure against
various health problems in ageing women. Amongst
hormone therapy's most recognized potential bene-
fits are a decrease in the risk of osteoporotic fractures
and cardiovascular disease, whilst its most serious
potential hazard is an increase in the risk of breast
cancer [1, 2]. The good prospects of use are mainly
based on results of lifelong use amongst American
women who run a relatively high risk of cardiovas-
cular disease [3].
Considering its commonness and its deadliness,
the frequency of cardiovascular disease is of over-
riding importance in the balance between benefits
Journal of Internal Medicine 2000; 248: 143±150
# 2000 Blackwell Science Ltd 143
and hazards. Shortly after menopause, the frequency
of cardiovascular disease is still low. Because the
frequencies of the disorders involved in the risk±
benefit balance vary with age and the hormone-
related effects may vary with the length of period of
use, starting age and duration of use become key
factors in determining the balance. These factors
even grow in significance, because in our view
adherence to a lifelong regimen on a large scale is
not a realistic assumption. Furthermore, populations
and countries differ in their risk of cardiovascular
disease. Therefore, a beneficial outcome of hormone
treatment in one country does not necessarily imply
a similar outcome in other countries.
The main rationale behind the choice of hor-
mones as a preventive measure is their assumed
potential to reduce cardiovascular disease, which is
based on results from observational studies. The
recently reported results of a clinical trial amongst
women with documented coronary heart disease
has cast doubt on this assumption: there was no
hormone-related reduction in cardiovascular events,
mainly as a result of a high number of events in the
treatment arm in the first year [4]. In the present
study, we focus on women of the general population.
It is not clear whether women without manifest
heart disease will be affected by the use of a
hormonal regimen in a similar way. Besides, the
results of the trial do not exclude an anti-athero-
genic effect of hormones in the longer run. There-
fore, we think it is most valid to use the estimates of
hormonal effects from observational studies for a
risk±benefit analysis in women of the general
population.
To date, several computer simulations have
attempted to weigh the risks and benefits of long-
term hormone replacement therapy [1, 5±8]. All but
one [6] refer to white American women. Each of the
simulations provides insufficient information to form
a well-founded opinion on the health gain attainable
for women when the use of hormones is continued
for a shorter period than whole of life. Either the
simulation studies have reported on health gains for
lifelong use and expressed the outcomes in terms of
mortality but not morbidity, which provides limited
insight into the risk±benefit balance [1, 7], or the
studies have paid attention to shorter than lifelong
use and have reported in more detail on the risk±
benefit balance, but have not provided outcomes for
women with different cardiovascular risk profiles
[5, 6]. The most recently published study, aimed at
helping women and their physicians to choose the
most beneficial therapy, combined all relevant
aspects of use in a simulation model [8]. Calcula-
tions were made for various durations of use as well
as for users with various risk profiles, and outcomes
on morbidity and mortality were reported. However,
the weighing of benefits against risks was carried out
for lifelong use and its effect on mortality only.
Results of this weighing process were further used as
a basis for the framing of a decision scheme.
We estimated the effect of hormone use for a
period of moderate duration on prolongation of life
through its effect on myocardial infarction, hip
fracture and breast cancer amongst a synthetic
cohort of Dutch women aged 55. We computed the
effect for women with an average and with a high-
risk profile for cardiovascular disease. In addition,
we computed hormone-related risk±benefit ratios for
the three diseases.
Methods
The model
Our simulation used a proportional multistage life
table which starts the calculations from disease
prevalences. It is specially designed to cope with a
large number of diseases simultaneously, whilst
allowing for co-morbidity [9]. Disease prevalences
were calculated from entered data on age-specific
incidence and excess mortality for heart attack, hip
fracture and breast cancer and on the risk of death
from other causes. The model starts at age 55 for all
women free from the three diseases under con-
sideration. For each life-year thereafter, the prob-
ability of a woman developing one of the diseases of
interest is calculated, or, in the case of a woman
who has become diseased, the probability of her
dying from it and the probability of her dying from
other causes. The effect of hormone use on
morbidity and mortality is modelled by changing
the probabilities to obtain one of the diseases under
consideration. Once a woman has become diseased,
she is assumed to have stopped using hormones. Her
subsequent survival is not affected by hormone use.
Figures on breast cancer were derived from the
Comprehensive National Cancer Registry [10] and
the Cancer Registry in the south-eastern Nether-
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lands [11]. Hip fracture figures came from a
nationwide hospital discharge registry and indivi-
dual studies on the survival of hip fracture patients
[12], and the risk of death from other causes came
from a national registry of causes of death [13]. Our
measure of heart attack incidence refers to clinically
manifest events, i.e. fatal events occurring inside or
outside the hospital and non-fatal events resulting in
hospital admission. Incidence and excess mortality
were derived from mortality statistics and hospital
discharge data using estimates of fatality rates and
risks of recurrent infarction from literature. Esti-
mated incidences were validated against observa-
tional data from the Rotterdam Study [14].
All incidences refer to 1992/1993 figures, with
the exception of breast cancer incidence which refers
to 1989 figures corrected for contralateral tumours.
This was done because in 1990 a nationwide
screening programme was implemented. The use of
hormones by Dutch women is limited after meno-
pause. An estimated 12% of the women in the age
range 45±60 years is taking hormone replacement
therapy, mainly for symptomatic reasons and
usually for a short period of time [15]. We therefore
assumed that the data sources referred to non-using
women.
We defined a group at high risk of myocardial
infarction using data from a population-based study,
the Rotterdam Study [16]. The criteria were being
diabetic or the presence of at least two of the
following risk factors: cigarette smoking, hyperten-
sion or hypercholesterolaemia. About 14% of the
women between the age of 55 and 64 met the
criteria of a high-risk profile (see Table 1). These
women were also more frequently obese and had a
20% greater chance of dying from non-cardiovas-
cular disease up to the age of 80 than the entire
group of women in the cohort (unpublished data).
We assumed the high-risk women to have a 100
(from age 70 onwards) to 150% (aged between 55
and 69) higher risk of myocardial infarction [17], a
5% higher risk of breast cancer because of their
obesity [2] and a 20% higher risk of overall death.
Hormonal effects
In our model, postmenopausal hormone use affects
the occurrence of first events. Following Grady et
al.'s [1] assumptions, we assumed that use of
hormone therapy ± oestrogens alone or in combina-
tion with progestins ± reduced the risk of myocardial
infarction by 36% and hip fracture by 25%. The
protective effects against heart attack and hip
fractures were assumed to take effect immediately
after the start of use. The risk of breast cancer was
assumed to increase only after 5 years of use and
then in a two-step fashion (relative risk: 6±10 years,
1.2; . 10 years, 1.35), based on the results of a
meta-analysis on the relation between hormone use
and breast cancer [2]. The effects of the use were
assumed to cease immediately after discontinuation.
The hormone-related relative risk reduction and
elevation in the high-risk group were assumed to be
similar to those in the population at large except for
the breast cancer risk. Since the latter risk is likely to
depend on the degree of obesity [2], we assumed a
slightly smaller effect in high-risk women (relative
risk: 6±10 years, 1.15; . 10 years, 1.3).
Outcome measures and analysis
Outcomes were measured in four ways: the absolute
changes in life expectancy and in the time period
free from heart attack, hip fracture and breast
cancer after the age of 55 (disease-free life ex-
pectancy); the number of women needing to under-
go treatment in order to prevent one woman from
developing a first heart attack or hip fracture
(number-needed-to-treat); and the risk±benefit ratio
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Table 1 Characteristics of all women aged 55±64 in the
Rotterdam Study and of a subgroup of women with a high-risk
profile for cardiovascular disease
All women
(n = 1381)
High-risk womena
(n = 196)
Diabetes mellitus (%) 5 33
Cigarette smoking (%)
Current 26 67
Past 32 15
Hypertensionb (%) 24 73
Hypercholesterolaemiac (%) 15 49
Quetelet index (kg m22)
< 25 44 34
$ 25 to < 27 21 20
$ 27 35 46
aDiabetic women or women with the presence of at least two of
the following risk factors: cigarette smoking, hypertension or
hypercholesterolaemia.
bSystolic blood pressure $ 160 mmHg and/or diastolic blood
pressure $ 95 mmHg or antihypertensive medication.
cTotal cholesterol $ 8 mmol L21.
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reflecting the absolute number of prevented cases of
first heart attack or hip fracture in relation to the
absolute excess number of cases of breast cancer. In
accordance with life expectancy, which is deter-
mined by the probability of dying per year of life, the
disease-free life expectancy is determined by the
probability of getting one of the diseases under
consideration or of dying from other causes per year
of life.
Among the main problems in establishing the size
of a hormone effect on the reduction of coronary
heart disease (CHD) are the various sources of bias in
observational studies which can considerably over-
rate the benefit of hormone use [18]. We therefore
made additional calculations for a 20% instead of a
36% reduction in risk of myocardial infarction. We
further performed a sensitivity analysis assuming a
20% higher or 20% lower incidence of heart attack,
hip fractures and breast cancer.
We report on women of the general population
and women at high risk for myocardial infarction
owing to their risk profile for both 10 and 20
consecutive years of use.
Results
The baseline life expectancy of a 55-year-old Dutch
woman not undergoing hormone therapy is another
27.2 years, of which she will have 23.7 years free
from heart attack, hip fracture or breast cancer.
Breast cancer occurs at a much younger age than
heart attack or hip fracture; the latter two condi-
tions become a major health problem after the age of
80 (Fig. 1). The absolute risk of a 55-year-old Dutch
woman of a first heart attack within 10 years is
2.8%, that of a first hip fracture is 0.8%, and that of
a clinical (not screening-detected) breast cancer
diagnosis is 2.1%. The figures for the risks within
20 years are 7.8, 3.5 and 4.5%, respectively.
An average woman of the general Dutch popula-
tion who starts hormone therapy at age 55 can
prolong her life by 1 month where she uses it for
10 years, and 2 months where she continues to use
it for 20 years (Table 2). She may postpone the
occurrence of first incidence of one of the three
diseases in question by 2.4 months where she uses
hormone therapy for 10 years, and by 5 months
where she continues to use it for 20 years. This
postponement is the net effect of a delay in the
occurrence of heart attack and hip fracture and an
acceleration in that of breast cancer. In order to
prevent one first heart attack or hip fracture, 83
women must use combined therapy for 10 con-
secutive years (Table 3). The number is lowered by
two-thirds when the use is prolonged to 20 years.
One excess breast cancer case is likely to occur per
5±6 averted cases of first myocardial infarction or
hip fracture for 10 years of use. The risk±benefit
ratio worsens to 3±4 averted cases per extra breast
cancer case when the use is prolonged to 20 years.
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Fig. 1 Age-specific incidence rates for women in the Netherlands.
Table 2 Gain in life expectancy and disease-free period for a 55-
year-old Dutch woman on hormone therapy during 10 or
20 years according to her cardiovascular risk profile; hormones
reduce CHD risk by 36%
Duration of use No use 10 years 20 years
Average risk
Life expectancy (years) 27.2 + 0.08 + 0.19
Disease-freea (years) 23.7 + 0.20 + 0.41
High-risk
Life expectancy (years) 25.8 + 0.19 + 0.43
Disease-freea (years) 21.6 + 0.46 + 0.90
aPeriod free of the three diseases under consideration.
Table 3 Number-needed-to-treat to prevent one first heart attack
or hip fracture and relative number of prevented cases per extra
incident of breast cancer (risk±benefit ratio) after 10 and 20 years
of hormone therapy according to the cardiovascular risk profile;
hormones reduce CHD risk by 36%
Average risk High risk
Duration of use 10 years 20 years 10 years 20 years
Number-needed-to-treat 83 28 38 15
Risk±benefit ratio 5.5 3.4 14.8 7.0
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In cases where a woman has a high-risk profile for
cardiovascular disease, her life expectancy is
17 months shorter and her disease-free period is
about 2 years shorter (Table 2). In that case, she
may prolong her life by well over 2 or 5 months,
and her disease-free period by 5.5 or almost
11 months, when use is continued for 10 or
20 years, respectively. Thirty-eight women need to
take hormones for a period of 10 consecutive years,
or 15 women for a period of 20 years, to prevent
one first heart attack or hip fracture (Table 3). The
balance between benefit and harm is also more
favourable than in the population at large. Yet the
risk±benefit ratio also worsens considerably for 20
as compared with 10 years of use.
If the existing estimates for CHD reduction are
overrated and the real reduction is half as large as
that assumed by Grady, then the gain in life
expectancy and disease-free life expectancy will be
halved (Table 4). This holds for both women with an
average and those with a high-risk profile for
cardiovascular diseases. The number-needed-to treat
and the risk±benefit ratio for both risk profiles would
then be 1.5±1.7 times less favourable (Table 5). The
sensitivity analysis for 20 years of hormone use
indicates that the incidence of myocardial infarction
determines gains in life expectancy (data not
shown). The risk±benefit relation is affected most
by changes in the incidence of breast cancer,
followed by those of heart attack. Changes in the
incidence of hip fracture do not affect life expectancy
and hardly affect the risk±benefit relation.
Discussion
Our data indicate that 10 or 20 consecutive years of
hormone therapy would offer only modest gains to
the general population of Dutch postmenopausal
women. The gains for women with a high cardio-
vascular risk profile, an estimated one-seventh of the
women in the age range 55±64 years, are con-
siderably larger than for the general population.
However, the risk±benefit ratio still worsens when
the duration of use is prolonged from 10 to
20 years.
The modest gain in life expectancy and disease-
free life expectancy for Dutch women using hor-
mones during 10 or 20 years following menopause
results from the low incidence of hip fractures and
CHD in relation to the relatively high incidence of
breast cancer in the age range 55±75 years. The
risk±benefit ratio worsens with the extension of use
from 10 to 20 years, irrespective of the cardiovas-
cular risk profile. The worsening of the ratio with
longer duration of use, even amongst high-risk
women, is a result of the hormone-related excess risk
of breast cancer which only becomes fully manifest
after long-standing use.
A white American woman can add one extra year
to her life when she continues the use of hormones
lifelong [1, 7] and a British woman can add one
extra year to her life when she continues the use for
20 years [6]. In comparison with American and
British women, the calculated 2 month gain after
20 years of use for Dutch women is limited. A
portion of the noted differences may be ascribed to
specific characteristics of the distinctive models. Our
assumptions on the size of a hormone-related effect
were on the conservative side. We were as modest in
our CHD effects as Grady et al. [1] and only Col et al.
[7] has assumed a more deleterious effect on breast
cancer.
The gain in life expectancy and disease-free period
for Dutch women might be smaller if the assumed
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Table 4 Gain in life expectancy and disease-free period for a 55-
year-old Dutch woman on hormone therapy for 10 or 20 years
according to her cardiovascular risk profile; hormones reduce
CHD risk by 20%
Duration of use No use 10 years 20 years
Average risk
Life expectancy (years) 27.2 + 0.04 + 0.08
Disease-freea (years) 23.7 + 0.11 + 0.21
High-risk
Life expectancy (years) 25.8 + 0.10 + 0.22
Disease-freea (years) 21.6 + 0.26 + 0.49
aPeriod free of the three diseases under consideration.
Table 5 Number-needed-to-treat to prevent one first heart attack
or hip fracture and relative number of prevented cases per extra
incident of breast cancer (risk±benefit ratio) after 10 and 20 years
of hormone therapy according to the cardiovascular risk profile;
hormones reduce CHD risk by 20%
Average risk High risk
Duration of use 10 years 20 years 10 years 20 years
Number-needed-to-treat 133 42 65 25
Risk±benefit ratio 3.4 2.3 8.9 4.4
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36% reduction in CHD is substantially biased. An
important source of bias is the healthy user effect:
women who use hormones on a long-term basis
have a more favourable risk profile for CHD than do
non-users [18]. A recent Swedish study that tried to
take account of the healthy user bias reported a 25%
reduction in risk of heart attack for long-term
hormone therapy with potent oestrogens [19].
Without such a correction, the reduction was
32%. If a 25% reduction is closer to the true
hormone effect, the profits of long-term hormone use
will converge to the results presented for the
hypothetical 0.8 estimate we used for a bias-free
CHD effect.
We did not consider the inclusion of stroke, as we
assumed the effect of hormone therapy on stroke
rates to be minimal, following Grady et al. [1]. Daly
et al. [6], however, assumed hormone therapy to
have a beneficial effect on stroke and included stroke
in their model. They also assumed a persisting
hormone-related effect on heart disease, hip fracture
and breast cancer after discontinuation of a 20-year
period of use. The latter assumption, in particular,
will have contributed substantially to the overall
gain in life expectancy, considering the increasing
burden of heart disease and hip fracture in older age.
So far, empirical data have not shown that, after
discontinuation of hormone use, the risk of dying
from heart disease remains reduced [20] or that the
risk of dying from breast cancer remains elevated
[2]. Furthermore, hip fracture risk is not reduced in
previous users [21]. We therefore did not assume a
persisting hormone effect.
We included only acute myocardial infarction and
deaths resulting from those infarctions ± acute and
in the long run ± in our model as measures for CHD,
in contrast with the other models. Because other
manifestations of CHD and their consequences for
health, such as heart failure, may also be preven-
table by hormone use, our restriction will under-
estimate the potential health gain. We applied this
restriction because the morbidity data available on
the other CHD diagnoses did not allow us to estimate
incidence and subsequent survival reliably. About
80% of the Dutch women who die from ischaemic
heart disease between the ages of 55 and 75 die
from a heart attack. When we used a slightly
different model, which included death from all
ischaemic heart disease, the gain of life for Dutch
women on hormone therapy was 30% greater than
that shown by the present model (data not shown).
Such a gain is still of modest size.
Not all heart attacks are brought to medical
attention, and of those that are, not all are
recognized as such, in particular in women. Because
our model is based on registered events, the figures
may underestimate the true heart attack incidence,
and thus the potential health gain. We do not know
to what extent. The sensitivity analysis showed that
if a woman from the general population has a 20%
higher chance of a heart attack than the registered
events indicate, she can prolong life by 2.5 instead of
2 months when she uses hormones for 20 years.
The corresponding risk±benefit ratio improves to 4
instead of 3±4 averted cases per extra case of breast
cancer. The other models against which we compare
our results are also based on registered events.
The most likely explanation for the relatively
limited gains in prolongation of life experienced by
Dutch women in comparison with American and
British women is the restriction of use to the early
postmenopausal years. In those years, the overall
baseline mortality and the baseline morbidity and
mortality patterns in heart disease differ consider-
ably between the populations. For example, British
[3] and American women [22] between the ages of
55 and 74 are more likely to die from any cause and
are also more likely to die from cardiovascular
disease, in particular CHD, than are Dutch women of
the same age group [3]. The reporting of potential
coronary deaths for the purpose of the registration of
causes of death varies by country [23]. For a
meaningful comparison of the hormone-related
outcomes, it is important to know to what extent
differences in recorded CHD mortality between
populations reflect real differences in coronary
events and to what extent they refer to varying
coding practices.
The number of 83 Dutch women with an average
cardiovascular risk profile who need to use a
combined regimen for 10 years in order to prevent
a first heart attack or hip fracture conveys the low
incidence of the preventable diseases shortly after
menopause. So does the corresponding risk±benefit
ratio of 5±6 prevented cases per extra breast cancer
case. When the use is continued, the number-
needed-to-treat becomes more favourable, but the
corresponding risk±benefit ratio becomes worse. The
hormone-related effects on morbidity, as opposed to
the effects on the prolongation of life, seem to be
1 4 8 C . J . M O E R M A N et al.
# 2000 Blackwell Science Ltd Journal of Internal Medicine 248: 143±150
even less advantageous in a population in which
cardiovascular disease is much more frequently
occurring. Whilst Daly et al. [6] showed that British
women can prolong their life substantially by
hormone use, they calculated one extra hospitaliza-
tion for breast cancer per two prevented admissions
for ischaemic heart disease or hip fracture between
the ages of 50 and 69 years if women were to use a
combined regimen for 10 years starting at age 50.
White American women also run a relatively high
risk of cardiovascular disease, as indicated by the
numbers-needed-to-treat reported by Col et al. [8].
Although that number becomes more favourable
when the use is extended from 10 to 20±30 years,
the corresponding risk±benefit ratios for women of
average cardiovascular and breast cancer risk
remain constant and not very favourable: 3±4
averted cases of CHD or hip fracture per extra case
of breast cancer.
Life expectancy is an overall measure in which the
contribution of the distinct diseases is not visualized.
The not so favourable risk±benefit ratios even for
American and British women indicate that in
populations of high cardiovascular risk as well, the
hormone-related increase in breast cancer risk
weighs heavily on the final outcome. This puts the
attainable profits of long-term hormone use in
another light. It warrants caution against planning
a preventive strategy on expected gains in life
expectancy alone, without a separate evaluation of
the effects on the risk and the benefit side of the
balance. Besides, the risk±benefit ratios show the
importance of including effects on morbidity, and
not just mortality, in weighing the pros and cons of
a preventive strategy.
In conclusion, with the existing risk estimates of
hormone therapy, our model projects only limited
gains for 10 or 20 years of hormone use by Dutch
women from the general population. They represent
a population of intermediate cardiovascular risk.
The gains are larger for women with a high
cardiovascular risk profile. However, even amongst
the high-risk women, the risk of breast cancer
incurred with long-term use offsets much of the
benefit that could accrue from changing the risk of
heart disease and hip fractures.
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